Morgan Stanley Upgrades ACADIA Pharmaceuticals to Overweight, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung upgraded ACADIA Pharmaceuticals (ACAD) from Equal-Weight to Overweight and increased the price target from $31 to $40.
December 19, 2023 | 2:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ACADIA Pharmaceuticals was upgraded by Morgan Stanley from Equal-Weight to Overweight with a raised price target from $31 to $40.
Upgrades by major analysts like Morgan Stanley can lead to increased investor confidence and potential stock price appreciation in the short term. The raised price target suggests a positive outlook on the company's future performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100